Berger Financial Group Inc Acquires 55,450 Shares of Abbott Laboratories $ABT

Key Points

• Berger Financial Group sharply increased its stake in Abbott Laboratories, boosting holdings by 899.4% in the first quarter to 61,615 shares valued at about $6.33 million.
• Abbott reported better-than-expected quarterly results, with EPS of $1.15 and revenue of $11.16 billion, both topping analyst estimates, and raised guidance for FY 2026 and Q2 2026.
• The company declared a quarterly dividend of $0.63 per share, implying an annualized payout of $2.52 and a yield of 2.6%, while analysts currently rate the stock a Moderate Buy with a consensus target of $118.42.

Berger Financial Group Inc boosted its holdings in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 899.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 61,615 shares of the healthcare product maker's stock after acquiring an additional 55,450 shares during the quarter. Berger Financial Group Inc's holdings in Abbott Laboratories were worth $6,326,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in ABT. Freemont Management S.A. boosted its position in shares of Abbott Laboratories by 197.2% during the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker's stock valued at $1,341,000 after purchasing an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab bought a new stake in Abbott Laboratories in the fourth quarter worth approximately $116,580,000. Danica Pension Livsforsikringsaktieselskab acquired a new position in Abbott Laboratories in the third quarter valued at approximately $185,640,000. Thrivent Financial for Lutherans boosted its holdings in shares of Abbott Laboratories by 24.3% during the 4th quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker's stock worth $30,931,000 after buying an additional 48,286 shares in the last quarter. Finally, Net Worth Advisory Group acquired a new stake in shares of Abbott Laboratories during the 4th quarter worth approximately $1,366,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Trading Down 0.2%

ABT opened at $95.25 on Friday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $137.49. The firm has a market capitalization of $165.91 billion, a PE ratio of 26.68, a P/E/G ratio of 1.64 and a beta of 0.61. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01. The company's 50-day moving average is $88.95 and its 200 day moving average is $104.35.

Abbott Laboratories (NYSE:ABT - Get Free Report) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. The firm had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a return on equity of 17.62% and a net margin of 13.90%.The company's revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the previous year, the company posted $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts predict that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories's payout ratio is currently 70.59%.

Analyst Ratings Changes

A number of research analysts recently issued reports on ABT shares. Evercore dropped their target price on shares of Abbott Laboratories from $134.00 to $120.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Leerink Partners decreased their price target on shares of Abbott Laboratories from $119.00 to $106.00 and set a "market perform" rating for the company in a research note on Tuesday, April 21st. Daiwa Securities Group lowered shares of Abbott Laboratories from an "outperform" rating to a "neutral" rating and set a $92.00 price objective on the stock. in a report on Wednesday, April 22nd. Oppenheimer cut their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an "outperform" rating on the stock in a research report on Friday, April 17th. Finally, Robert W. Baird started coverage on Abbott Laboratories in a research report on Wednesday. They issued an "outperform" rating and a $121.00 target price for the company. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, Abbott Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $118.42.

Insiders Place Their Bets

In other news, CFO Philip P. Boudreau bought 2,200 shares of Abbott Laboratories stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer directly owned 2,200 shares in the company, valued at $201,300. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel J. Starks purchased 10,000 shares of the business's stock in a transaction that occurred on Monday, April 27th. The shares were purchased at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the acquisition, the director owned 6,751,103 shares of the company's stock, valued at $625,489,692.95. The trade was a 0.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by insiders.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.